Invesco Ltd. Has $6.83 Million Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR

Key Points

• Invesco Ltd. has increased its stake in Structure Therapeutics Inc. by 6.1%, now owning 394,386 shares valued at approximately $6.8 million.
• Several hedge funds have also significantly increased their holdings in Structure Therapeutics, with Deep Track Capital LP growing its stake by 129.4% in the last quarter.
• Analysts have set new price targets for Structure Therapeutics, with a consensus rating of "Buy" and an average price target of $75.71, reflecting varying outlooks from different financial institutions.

Invesco Ltd. grew its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 6.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 394,386 shares of the company's stock after acquiring an additional 22,619 shares during the period. Invesco Ltd. owned about 0.69% of Structure Therapeutics worth $6,827,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new position in shares of Structure Therapeutics in the 4th quarter valued at about $34,000. National Bank of Canada FI grew its position in shares of Structure Therapeutics by 1,448.2% in the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock valued at $51,000 after acquiring an additional 2,766 shares during the period. Virtus ETF Advisers LLC grew its position in shares of Structure Therapeutics by 25.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after acquiring an additional 455 shares during the period. ANTIPODES PARTNERS Ltd grew its position in shares of Structure Therapeutics by 310.7% in the 1st quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company's stock valued at $74,000 after acquiring an additional 3,213 shares during the period. Finally, Tower Research Capital LLC TRC grew its position in shares of Structure Therapeutics by 673.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,076 shares of the company's stock valued at $111,000 after acquiring an additional 3,549 shares during the period. Institutional investors own 91.78% of the company's stock.

Structure Therapeutics Price Performance

Structure Therapeutics stock traded up $0.16 during midday trading on Friday, hitting $19.30. The company's stock had a trading volume of 514,636 shares, compared to its average volume of 863,697. Structure Therapeutics Inc. Sponsored ADR has a 1-year low of $13.22 and a 1-year high of $45.37. The company has a 50-day moving average price of $19.01 and a two-hundred day moving average price of $20.84. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -18.38 and a beta of -1.89.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.08). Sell-side analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

Wall Street Analysts Forecast Growth

GPCR has been the subject of a number of analyst reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $65.00 price objective on shares of Structure Therapeutics in a research report on Monday, June 23rd. JMP Securities decreased their price objective on shares of Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating for the company in a research report on Thursday, August 7th. HC Wainwright reduced their target price on shares of Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating for the company in a report on Thursday, August 7th. Finally, Guggenheim reduced their target price on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating for the company in a report on Thursday, August 7th. Eight analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $75.71.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.